TCL Archive DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program October 25, 1985
TCL Archive Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer July 31, 2009
TCL Archive In Brief: McDonnell Foundation Selects Five For $400,000 Fellowships; Alberts, Verma Picked For Awards January 4, 1991
TCL Archive In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads August 8, 1980
